Search
for

    Learn

    5 / 801 results

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community The New, Improved CB-03-01/Setipiprant Group Buy

       29 upvotes 9 years ago
      The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

      community Wrap it up everyone. CB-03-01 is another failed treatment

      in Treatment  81 upvotes 7 months ago
      CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

      community Why doesn't phase 3 of PP405 start straight away?

      in Chat  14 upvotes 4 months ago
      Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

      community New Breezula Update ( I think)

      in Treatment  18 upvotes 5 months ago
      Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

      community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news

      in Chat  13 upvotes 5 months ago
      Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.